Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

MDR

- PMLiVE

Channel strategy in pharma

Channel strategy could be a significant 'stone unturned' in the battle to win customers and patients

Teva facing $2bn liability for at-risk generic Protonix launch

Potential litigation costs from Pfizer are triple the generics firm's original estimates

- PMLiVE

Building brand strength – Part 4

Commitment, responsiveness and protection – how far will Big Pharma go to preserve its brands?

EU flag

Five pharma companies begin antibiotic research programme

Sanofi, GSK and AstraZeneca among the collaborators on European projects

- PMLiVE

FDA proffers guidance for new Alzheimer’s drugs

Encourages approach that tackles disease in its early stages

- PMLiVE

Pfizer UK transfers online male health clinic to charity

Hands over Man MOT initiative to the Men's Health Forum

- PMLiVE

Strong start for Pfizer spin-out Zoetis

Animal health unit makes stock market debut

- PMLiVE

Pfizer revenues decline in Q4 but profits surge

Lipitor patent loss continues to hit sales

- PMLiVE

Pfizer launches chronic pain forum

Twitter style comments are used to help patients describe their conditions

- PMLiVE

NICE backs BMS-Pfizer’s Eliquis in atrial fibrillation

Final draft guidance recommends the drug for common heart condition

- PMLiVE

Pfizer gets CHMP backing for leukaemia drug bosutinib

Provides option for patients resistant to tyrosine kinase inhibitors

- PMLiVE

IQWiG finds some value in Pfizer’s Inlyta

Cost effectiveness body decides cancer drug has benefits over Bayer's Nexavar

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links